Two-dose daclizumab induction therapy in 209 liver transplants: A single-center analysis

Transplantation

Volumn 78, Issue 8, 2004, Pages 1212-1217

  Sellers, Marty T ^a,b   McGuire, Brendan M ^c   Haustein, Silke V ^b,d   Bynon, John S ^b   Hunt, Sharon L ^b   Eckhoff, Devin E ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Kentucky   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Daclizumab; Induction therapy; Liver transplantation

Indexed keywords

ACICLOVIR; CALCINEURIN INHIBITOR; CREATININE; DACLIZUMAB; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; AGE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RECURRENT INFECTION; RETROSPECTIVE STUDY;

ANTIBODIES, MONOCLONAL; CREATININE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREOPERATIVE CARE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 7044227570     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000138100.72757.BA     Document Type: Article

References (18)

1. Hirose R, Roberts JP, Quan D, et al. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. Transplantation 2000; 69: 307.
2. Ahsan N, Holman MJ, Jarowenko MV, et al. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. Am J Transplant 2002; 2: 568.
3. Ciancio G, Burke GW, Suzart K, et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation 2002; 73: 1100.
4. Bumgardner GL, Hardie I, Johnson RW, et al. Phase III Daclizumab Study Group. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation 2001; 72: 839.
5. Yan LN, Wang W, Li B, et al. Single-dose daclizumab induction therapy in patients with liver transplantation. World J Gastroenterol 2003; 9: 1881.
6. Niemeyer G, Koch M, Light S, et al. Long-term safety, tolerability and efficacy of daclizumab (Zenapax) in a two-dose regimen in liver transplant recipients. Am J Transplant 2002; 2: 454.
7. Emre S, Gondolesi G, Polat K, et al. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function. Liver Transplant 2001; 7: 220.
8. Neuhaus P, Clavien PA, Kittur D, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transplant 2002; 8: 132.
9. Heffron TG, Smallwood GA, Pillen T, et al. Liver transplant induction trial of daclizumab to spare calcineurin inhibition. Transplant Proc 2002; 34: 1514.
10. Eckhoff DE, McGuire B, Sellers M, et al. The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. Transplantation 2000; 69: 1867.
11. Eckhoff DE, McGuire BM, Frenette LR, et al. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. Transplantation 1998. 65: 180.
12. Pugh RH, Murray Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646.
13. Nelson DR, Soldevila-Pico C, Reed A, et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transplant 2001; 7: 1064.
14. Charlton MR. Mycophenolate and hepatitis C: salve on a wound or gasoline on a fire? Liver Transplant 2002; 8: 47.
15. De Vera ME, Smallwood GA, Rosado K, et al. Interferon-α and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation 2001; 71: 678.
16. Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998; 28: 638.
17. Haustein SV, McGuire BM, Eckhoff DE, et al. Impact of non-compliance and donor/recipient race matching on chronic liver rejection. Transplant Proc 2002; 34: 1497.
18. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931.